Entera is on the Cusp of the Trial That Could Unlock America's Osteoporosis Drug Market (NASDAQ: ENTX)

WSW, NY, August 31st, 2026, FinanceWire

The drugs that rebuild bone are locked inside a channel most patients never reach. Entera (NASDAQ: ENTX) is nearing the pivotal trial built to change that, with a fully funded balance sheet, and an opportunity to completely change the treatment paradigm, in a multi-billion dollar market.

Twice a year, a 68-year-old woman sits across from the doctor who knows her best, her gynecologist or her primary care physician, and reviews a bone scan that is quietly getting worse. The drug class that could rebuild her bone exists, and has for two decades. Her doctor, in most cases, cannot prescribe it.

The reason is a wall of logistics, not medicine. Every approved anabolic, the class that builds new bone rather than only slowing its loss, requires injections, prescribed largely through specialist channels built around injection training, in-office administration, buy-and-bill and reimbursement red tape. Rheumatology and endocrinology clinics are built for that. The primary care and gynecology offices where most postmenopausal women are actually seen are not. The outcome reads like a market failure: fewer than half of America's roughly 10 million diagnosed patients receive any therapy, and published estimates put anabolic use at roughly 15% of treated patients. That is both the beachhead and the prize: an anabolic market that already mints blockbusters from a sliver of the prescriber base, and an untreated majority that runs into the millions.

The company built for the locked door

Entera (NASDAQ:ENTX), a clinical-stage company specializing in oral peptides, exists to remove exactly that wall. Its lead program, EB613, is a once-daily oral tablet of PTH(1-34), the same peptide as Lilly's (NYSE:LLY) Forteo, and, the only once-daily oral anabolic tablet in development. A tablet needs no injection training and no specialty channel; it could be prescribed by the primary care physicians and gynecologists who actually manage these women. And the prescriber side looks ready for one: in physician survey data published by Entera, willingness to prescribe an anabolic among clinicians treating osteoporosis jumps from 12% to 92% once the anabolic is a tablet.

The last time a blockbuster peptide became a pill

Markets have seen this move before, which is helpful in framing the potential opportunity for oral osteoanabolic peptide. When Novo Nordisk (NYSE:NVO) turned its blockbuster injectable peptide semaglutide into a tablet, the oral version, Rybelsus, grew into a $3.4 billion product by 2024, up 26% that year, while the injectable grew 26% right alongside it. The pill did not split the market. It expanded the class.

Osteoporosis anabolics start from the same setup. Even confined to the needle and its narrow channel, Forteo peaked at approximately $1.7 billion in annual sales in 2017, and Amgen's (NASDAQ:AMGN) Evenity grew 34% last year to $2.1 billion. Even partial movement from today's roughly 15% share toward the roughly 38% share surveyed clinicians assigned an oral anabolic, across ten million diagnosed patients, describes a market several times the size of the one already minting two-billion-dollar drugs.

The pivotal trial’s moment is about to arrive

Entera is now on the cusp of the pivotal trial, and the past three months supplied all the pieces that enable it. In June, the FDA provided Entera with positive feedback on the registrational plan: a single 12-month Phase 3 in approximately 750 patients, built on the total hip bone density endpoint regulators formally qualified in December 2025, expected to begin late this year. In July, the leading funds in biotech financed it, through an oversubscribed $275 million private placement that fully funds the program through NDA submission. And on August 18, the company announced another important signal: Riccardo Paolo Camisasca, M.D., was appointed Chief Medical Officer, in the company's own words, "ahead of planned EB613 Phase 3 initiation."

Camisasca arrives with three decades of global development experience, most recently as Global Head of R&D at Sumitomo Pharma Switzerland, with earlier posts at Takeda and Novartis and a decade in endocrinology at Milan's San Raffaele hospital. His stated mandate is execution: to "execute the EB613 Phase 3 program with the discipline required for registrational development." CEO Miranda Toledano described the company as transitioning "into late-stage clinical execution." From there the calendar is legible: Phase 3 initiation late this year, an EB612 IND targeted for the first half of 2027, and topline in the second half of 2028. For a small-cap biotech, that is a rare configuration: the question is not whether the answer gets funded, but what the answer is.

Drug development carries risk, a single Phase 3 readout can fail, and biotech valuations are volatile. However, the story is worth watching closely. The locked channel already produces $1.7 billion and $2.1 billion drugs. The doctors have said what they would do with a tablet. The precedent shows how oral peptides expand their class rather than splitting it. And the company behind the only once-daily oral anabolic in development is valued at under $600 million, less than a third of Forteo's best single year of revenue. Now, the trial that could unlock the treatment gap has its start window, with funding in place from the top funds, and new leadership signaling its upcoming planned initiation.

Recent News Highlights from Entera (NASDAQ: ENTX):

Entera to Participate in Upcoming Fall Investor Conferences

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

Entera Announces Second Quarter 2026 Financial Results and Business Updates

Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Entera Bio Ltd. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact